Clinical trials in Guimaraes – page 33

686 clinical trials in Guimaraes, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Guimaraes at a glance

686

clinical trials

Research sites1

Quick filters

686 trials in Guimaraes

Open in trial search

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:AstraZeneca AB

Contact Research Centre

Neovascular age-related macular degeneration

Not recruiting

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:4d Molecular Therapeutics Inc.

Contact Research Centre

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug

Portugal

Participants:0–17 years
Substances:Empagliflozin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Goserelin Acetate
Sponsor:Novartis Pharma AG

Contact Research Centre

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Bemarituzumab
Sponsor:Amgen Inc.

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Novo Nordisk A/S

Contact Research Centre

Anxiety+1

Not recruiting

Comparison of oxazepam 50 mg orodispersible tablets and oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo

Comparison of oxazepam 50 mg orodispersible tablets and oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo

Portugal

Participants:18–64 years · Healthy volunteers
Substances:Oxazepam
Sponsor:Neuraxpharm Pharmaceuticals S.L.

Contact Research Centre

Nicotine dependence

Not recruiting

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug

Portugal

Participants:18–64 years · Healthy volunteers
Substances:Cytisinicline
Sponsor:Achieve Life Sciences Inc.

Contact Research Centre

Systemic scleroderma+3

Not recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Artiva Biotherapeutics Inc.

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Guimaraes

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis cardiomyopathy and treatments for hypertrophic cardiomyopathy. Research includes evaluations of new therapies for stroke prevention in patients with atrial fibrillation.

Heart Disease Management
Stroke Prevention
Cardiovascular Risk Reduction

Multiple trials examining breakthrough treatments for various forms of heart disease and their complications.

02 Respiratory Medicine

Clinical investigations into chronic rhinosinusitis treatments, both with and without nasal polyps. Studies evaluating new therapeutic approaches for respiratory conditions.

Nasal Polyp Treatment
Rhinosinusitis Management
Community-Acquired Pneumonia

Comprehensive research aimed at improving respiratory health outcomes and patient quality of life.

03 Neurological Disorders

Advanced research into multiple sclerosis and Alzheimer's disease related conditions. Studies focus on innovative treatments for both disease management and symptom control.

MS Treatment Development
Alzheimer's Psychosis
Epilepsy Management

Cutting-edge trials exploring new therapeutic options for various neurological conditions.

Back to Portugal All countries